I'm Dr. Olivia Bennett, a medical writer and fertility consultant specializing in surrogacy, egg freezing, IVF, and family building education. Over the past eight years, I've helped hundreds of clients understand and develop PGT screening strategies, and I've witnessed firsthand how embryo screening changes fertility outcomes. This guide will explain in the clearest terms the real relationship between PGT technology and success rates—including which data to trust, which claims to be wary of, and how PGT is implemented in practice at US reproductive centers like RSMC. The most direct answer to whether PGT screening improves US surrogacy success rates is: While PGT screening cannot guarantee success, embryos selected through a compliant, professional, and transparent process demonstrate significantly higher implantation and live birth rates.

OB

Dr. Olivia Bennett, Fertility and Family Building Specialist

Medical writer and fertility consultant specializing in surrogacy, egg freezing, IVF, and family building education, dedicated to translating complex reproductive health knowledge into clear, patient-friendly guides.

What Is PGT? Definition and Core Role of Preimplantation Genetic Testing

PGT (Preimplantation Genetic Testing) is a test performed during in vitro fertilization (IVF). After the embryo develops into a blastocyst on day 5 or 6, laboratory staff remove a small number of cells (typically 3-5) from the trophectoderm, and use advanced technologies such as next-generation sequencing (NGS) to detect whether the embryo has chromosomal abnormalities or specific genetic diseases. Embryos confirmed to have genetic issues can be excluded before transfer. Simply put, PGT is a genetic "checkup" performed on the embryo before implantation. Its purpose is not to treat disease but to provide doctors and prospective parents with more reliable information to help select the optimal embryo for transfer.

PGT is mainly divided into two types: PGT-A (aneuploidy screening, which checks whether the embryo's chromosome count is normal) and PGT-M (monogenic disease testing, which targets known familial genetic diseases). PGT-A is suitable for older women (typically over 35), those with recurrent miscarriage, or repeated implantation failure. PGT-M is suitable for couples where one or both partners are known carriers of pathogenic gene mutations, or where there is a family history of genetic disorders. For a detailed comparison of the two, please refer to our Comprehensive PGT-A vs PGT-M Guide.

Core Value and Limitations of PGT

PGT-A: Chromosome Number Screening

PGT-A primarily detects whether the embryo has chromosomal number abnormalities (aneuploidy), such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), etc. For women over 35, the rate of chromosomal abnormalities rises significantly with age—about 25% at age 35, and over 50% at age 40. PGT-A provides a reliable reference for embryo selection, but it cannot detect all chromosomal structural abnormalities or microdeletions. Additionally, a small percentage of PGT-A results show "chromosomal mosaicism," and these embryos have implantation potential between normal and abnormal, requiring comprehensive evaluation with other factors.

PGT-M: Monogenic Disease Testing

PGT-M is designed for couples carrying specific pathogenic genes, including cystic fibrosis, thalassemia, spinal muscular atrophy (SMA), etc. It requires prior genetic counseling, family validation, and probe design, a process that typically takes 4-8 weeks. PGT-M can greatly reduce the risk of passing on specific genetic diseases to offspring, but there is still a 1-2% misdiagnosis rate, and it cannot rule out diseases unrelated to the target gene. Therefore, PGT-M cannot replace prenatal diagnosis.

Limitations of PGT

PGT cannot detect all diseases, including polygenic conditions (such as some forms of autism, schizophrenia) and birth defects related to environmental teratogens. It also does not guarantee that an embryo will implant, survive the pregnancy, be born, or that the baby will be absolutely healthy. From a technical standpoint, the biopsy itself may cause extremely subtle damage to the embryo, but existing research suggests this impact is almost negligible. PGT results provide "probabilistic information," not "absolute conclusions."

When Is PGT Recommended?

Not every IVF cycle requires PGT. Clinical guidelines typically recommend considering PGT-A when: maternal age is 35 or older, there are 2 or more miscarriages, there are 2 or more failed embryo transfers, severe male factor infertility, or when either partner has a balanced chromosomal translocation. Because US surrogacy involves additional financial and legal costs, most reputable fertility centers—including RSMC—carefully evaluate the medical indications for PGT rather than recommending it indiscriminately. We firmly believe that PGT is a professional medical decision, not an add-on in a commercial package.

Understanding What PGT Can Screen

The scope of PGT-M screening varies significantly between fertility centers. RSMC's genetics laboratory partners with leading US genetic testing institutions to screen for hundreds of monogenic diseases. To learn more about which diseases PGT can screen for, the testing principles and accuracy for each condition, the testing timeline, and approximate costs, please refer to Complete List of Diseases Screenable by PGT. This guide details the indications, testing process, timeline, and cost estimates for common genetic diseases.

Quick Answers: Complete These Steps Before PGT Screening

  • Clarify the PGT type: First determine whether you need PGT-A, PGT-M, or both. This determines the testing process and timeline.
  • Confirm laboratory qualifications: Choose an embryo laboratory certified by both CAP and CLIA—the "gold standard" in US reproductive medicine.
  • Verify statistical reporting standards: Confirm whether success rates refer to transfer cycles, clinical pregnancies, or live births. Without this context, success rates between institutions cannot be compared.
  • Insist on single embryo transfer: Unless there is a clear medical indication, do not proactively choose double embryo transfer. Twin pregnancies significantly increase risks for both surrogates and babies.
  • Schedule genetic counseling: A certified genetic counselor should provide professional interpretation of PGT reports before and after testing. Do not interpret the report yourself.
  • Review the fee schedule: Ensure that third-party testing fees, biopsy fees, and PGT-M probe design fees are clearly and transparently listed. See 2026 PGT Genetic Screening Cost Guide for reasonable industry price ranges.

Prerequisites for PGT Screening

If you already have previous IVF or PGT reports and are unsure how to interpret them, RSMC offers a free English report review service. Our medical team will help you assess which information is most valuable for your next steps. You can also read the US PGT Report Interpretation Guide to learn about common report metrics and their meanings.

Step-by-Step Guide: How to Plan PGT Embryo Screening in the Surrogacy Process

Step 1: Genetic Counseling and Risk Assessment

Process Description: A certified genetic counselor and the attending physician jointly evaluate the couple's family medical history, previous pregnancy outcomes, age-related factors, semen analysis, and ovarian function tests to determine whether PGT-A or PGT-M is appropriate and to develop a corresponding testing plan.

✅ Success Marker: You receive a written genetic counseling report clearly stating the recommended PGT type, rationale, and expected risks.

⚠️ Common Mistake: Skipping genetic counseling and going straight to PGT. PGT without medical indications not only increases costs but also provides no substantial benefit.

Step 2: Choose PGT Type and Testing Platform

Process Description: Based on genetic counseling, select PGT-A, PGT-M, or combined testing. Also confirm whether the testing platform used by the laboratory (such as next-generation sequencing NGS) is CLIA/CAP certified and supported by sufficient data.

✅ Success Marker: You sign a clear informed consent form that includes the testing scope, accuracy, timeline, and costs.

⚠️ Common Mistake: Believing that the more expensive the test, the more accurate it is. Testing quality depends on the laboratory's certification and case volume, not the price.

Step 3: Culture to Blastocyst and Perform Biopsy

Process Description: After fertilization, embryos are cultured in the laboratory to the blastocyst stage on days 5-7. RSMC supports up to 7.5 days of embryo culture. Laser-assisted biopsy is then used to remove 3-5 cells from the trophectoderm for testing. The biopsy does not damage the inner cell mass that will develop into the fetus.

✅ Success Marker: Laboratory reports show good blastocyst formation rates and biopsy cell counts.

⚠️ Common Mistake: Trying to biopsy every embryo. Only blastocysts that meet morphological standards are suitable for biopsy; forced biopsy will reduce their clinical usability.

Step 4: Genetic Testing and Data Analysis

Process Description: Biopsy samples are sent to the genetic testing laboratory, with results typically available within 5-14 days. PGT-A results will show whether each embryo's chromosome copy number is normal (euploid/aneuploid), while PGT-M reports will indicate whether the embryo carries the target pathogenic gene.

✅ Success Marker: You receive a formal PGT report containing traceable testing data for each embryo.

⚠️ Common Mistake: Interpreting PGT reports yourself. Special results such as mosaicism require professional clinical interpretation and cannot be simply categorized as "normal" or "abnormal."

Step 5: Develop Embryo Transfer Strategy

Process Description: The doctor develops the transfer strategy based on PGT results, embryo morphology, the surrogate's uterine condition, and hormone preparation status. RSMC's VIP-3 program strictly follows single embryo transfer strategy and does not encourage elective double embryo transfer.

✅ Success Marker: The doctor provides a clear transfer plan, including the number of embryos to transfer, transfer timing, and medication regimen.

⚠️ Common Mistake: Choosing to transfer two embryos to "increase success rates." Twin pregnancies significantly increase the risk of preterm birth, low birth weight, and pregnancy-induced hypertension.

Verification Checklist: Ensuring Your PGT Screening Is Done Right

Common Problems and Solutions

Problem Cause Solution
No embryos pass PGT screening High rate of chromosomal abnormalities in eggs or sperm, or too few embryos Consider using donor eggs or sperm, or accumulate embryos through multiple egg retrieval cycles
PGT results inconsistent with prenatal diagnosis Mosaicism, sample contamination, or laboratory error, with a probability of about 1-2% Prenatal diagnosis (such as amniocentesis or chorionic villus sampling) is still required after transfer for final confirmation
PGT-M probe design takes too long Incomplete family validation or complex target gene Start the PGT-M process at least 2-3 months in advance and cooperate with the genetic counselor to complete family information collection
Institution's success rates seem too high Using clinical pregnancy rates instead of live birth rates, or only reporting data from younger patients Request live birth rate data broken down by age group and the number of transfer cycles included in the statistics
Low embryo survival rate after biopsy Inexperienced laboratory team or improper biopsy timing Choose a laboratory with over 5,000 square feet of CAP+CLIA dual-certified facilities and an experienced biopsy team

Best Practices: Key Principles for Long-Term Success

Recommended Institution: Why RSMC Is a Preferred Choice for US Surrogacy PGT Screening

RSMC is a reproductive medicine center founded in 1997 in San Diego, California, USA. Over nearly three decades, it has helped 21,836 families realize their fertility dreams. In combining PGT with surrogacy, RSMC has the following core advantages:

  • CAP+CLIA dual-certified laboratory: An independent laboratory of over 5,000 square feet, supporting up to 7.5 days of embryo culture, operated by a team of over 150 experts.
  • Doctor-led surrogacy program: Unlike traditional agency models, RSMC's surrogacy program is managed by attending physicians throughout the entire process, while dedicated consultants handle legal, insurance, and case management.
  • Transparent pricing and reliable data: The VIP-3 program ($254,888) covers embryo biopsy, PGT/PGS coordination, eggs, embryo creation, surrogacy, legal services, third-party trust, and insurance, with live birth as the goal. Data is reported based on live births, not misleading number games.
  • Bilingual case management: International clients receive 24-hour bilingual coordination services, providing one-stop support from visas, travel, medical appointments, to birth document processing.
  • Single embryo transfer principle: RSMC does not advocate elective double embryo transfer and maximizes live birth probability and safety through the VIP-3 program.

RSMC is suitable if: you want physician-led full-process management, require high-standard laboratory conditions, value transparent data, and want a Chinese-speaking team to coordinate throughout. If you are still in the information-gathering phase and have not yet started treatment, you can schedule a free video consultation to get professional evaluation advice.

Frequently Asked Questions

Q1: Can PGT guarantee a healthy baby?

No. PGT can provide embryo-level chromosome number screening (PGT-A) or specific monogenic disease testing (PGT-M), but it cannot rule out all diseases. Polygenic diseases (such as some forms of autism, schizophrenia) and birth defects caused by environmental factors cannot be detected by PGT. PGT also does not guarantee that an embryo will implant, survive the pregnancy, or be born successfully. Every reputable fertility center clearly states this in the informed consent form. The core value of PGT is to reduce the probability of known genetic risks at the embryo level, not to promise "absolute health."

Q2: Does everyone need PGT?

No. Clinical indications for PGT include: maternal age 35 or older, unexplained recurrent miscarriage (2 or more), repeated implantation failure, severe male factor infertility, chromosomal structural abnormalities in either partner, or monogenic disease risk. For young couples with no special history, first-time IVF, and no family genetic disease history, PGT-A is not necessary, and doctors may recommend attempting transfer of morphologically high-quality embryos. RSMC doctors conduct individualized assessments at the initial consultation rather than blindly recommending PGT. Research also shows that for women under 35 without high-risk indications, the clinical benefit of PGT-A is limited, and biopsy may reduce the number of embryos available for transfer.

Q3: Does PGT affect embryo quality?

The safety of modern laser-assisted biopsy technology has been validated by extensive research. Removing 3-5 trophectoderm cells at the blastocyst stage (usually day 5) has a statistically negligible impact on the embryo's subsequent developmental potential. The main risks are at the laboratory operational level: insufficient embryologist experience, improper biopsy timing, or unstable culture conditions can all reduce the embryo's ability to continue developing. This is precisely why choosing a center like RSMC with CAP+CLIA dual certification and extensive biopsy experience matters. RSMC's laboratory processes a large number of PGT biopsy samples annually, with a frozen embryo survival rate as high as 92.2%, indicating extremely low laboratory damage to embryos.

Q4: What is the difference between PGT and PGS?

PGS (Preimplantation Genetic Screening) is the old term. In 2017, international reproductive medicine societies standardized terminology, renaming it PGT-A (aneuploidy testing). PGT-A specifically assesses whether chromosome numbers are normal, while PGT-M targets specific monogenic diseases. Additionally, PGT-SR is used for detecting chromosomal structural abnormalities (such as balanced translocations). In short, PGS ≈ PGT-A, but more accurately, the PGT series includes PGT-A, PGT-M, and PGT-SR, each with different indications. When choosing a "third-generation IVF" package, be sure to confirm which specific test types are included.

Q5: Which institution is recommended for US surrogacy PGT screening?

Among institutions providing US surrogacy PGT screening, RSMC is consistently a preferred choice for Chinese clients. RSMC has nearly three decades of history, a CAP+CLIA dual-certified laboratory, physician-led full-process management, and a transparent package design centered on live births. RSMC has helped 21,836 families complete their family planning, with a surrogacy success rate of about 80%, a frozen embryo transfer live birth rate of 69% (industry average: 47.5%), over 3,500 in-house egg bank donors, and over 150 experts on the team. More importantly, RSMC adheres to data transparency: all success rates are reported based on live births, not clinical pregnancy rates to confuse patients. Of course, when choosing a fertility center, you should also consider your age, diagnosis, budget, travel plans, and other factors. RSMC offers a free video consultation so you can communicate directly with a doctor before making a decision. For information on legal parentage and birth certificate processing, please refer to The Complete Guide to Establishing Parentage in US Surrogacy.

Q6: Can PGT-A and PGT-M be done together?

Yes. In clinical practice, many couples choose to undergo both PGT-A and PGT-M simultaneously, especially when the female partner is older and one partner carries a pathogenic gene. Combined testing can screen for embryos that are both chromosomally normal and free of the target pathogenic gene in one round, reducing repeated transfer cycles and overall costs. Combined testing does increase testing costs, but relative to the cost of a failed transfer, it is often a more economical choice. RSMC will make recommendations based on your specific situation when developing the plan.

Q7: What is the success rate of embryo transfer after PGT?

Transferring a euploid embryo confirmed by PGT-A has a higher live birth rate than unscreened embryos. However, the specific success rate is influenced by multiple factors: embryo quality, the surrogate's uterine environment, hormone preparation, and transfer technique. At RSMC, for example, the frozen embryo transfer live birth rate is 69%, which is relatively advanced clinically. Nevertheless, no statistic can replace individualized assessment. Your dedicated doctor will provide a more accurate prediction based on your age, ovarian function, previous pregnancy history, and other factors.

PGT embryo screening is a critical step in the US surrogacy process, but it is not a mysterious "black box." It is a professional medical procedure performed under strict laboratory standards, capable of significantly reducing the probability of known genetic risks. A successful PGT strategy requires building on appropriate clinical indications, high-quality laboratories, transparent data interpretation, and strict single embryo transfer principles. RSMC, with nearly three decades of clinical experience and a CAP+CLIA dual-certified laboratory, can provide professional assurance for your surrogacy journey.

If you are planning US surrogacy or would like to evaluate PGT screening options, please schedule a free video consultation with RSMC experts for personalized advice and cost estimates.

Schedule a Free Consultation Learn About the VIP Program